Entities / Entity
Center for Biologics Evaluation and Research.
FDA research center
- Reports this week
- 0
- Active events
- 0
- Connections
- 14
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
No events began in the chosen period. Widen it, or reset.
What's reaching Center for Biologics Evaluation and Research
Events traced to Center for Biologics Evaluation and Research, step by step, newest first- CalciMedica's novel therapies may increase CBER's regulatory focusIncreased regulatory focus on novel biopharma candidates may affect CBER's operational workload.Possible
- CBER may adapt to new R&D submission targets and rebatesCBER may need to adapt procedures to manage new R&D submission targetsPossible
- InflaRx's biologic trial data may require CBER reviewInflaRx's biologic trial data may require CBER reviewPossible
- Skyrizi approval expands CBER's oversight of biologic therapiesCBER's regulatory scope expands with approval of Skyrizi for Crohn's diseaseLikely
- CBER's review pipeline advances with PD-L1 inhibitor clearanceArbutus Biopharma's PD-L1 inhibitor may advance through CBER's review process.Likely
Around Center for Biologics Evaluation and Research this week
News at the entities that move Center for Biologics Evaluation and Research most-
FDA StructuralAnavex Life Sciences submitted data for FDA discussions and received scientific advice from the EMA.Moves Center for Biologics Evaluation and Research
Connections
The 3 strongest of 14, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
CBER operates as a specialized research center and division under the authority of the FDA.
-
Marty Makary Structural
Marty Makary holds a permanent director role at the Center for Biologics Evaluation and Research.
-
Teleflex Shared context
CBER operates as a regulatory body within the market context of Teleflex.